Pedeks

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pedeks

Quick Facts

Property Description
Active ingredient Permethrin
Form Topical Preparation (Cream or Lotion)
Pharmacological class Scabicide and Pediculicide
Common use Elimination of ectoparasite infestations
Origin Synthetic pyrethroid

Pedeks is a topical ectoparasiticide medicinal preparation containing the active ingredient Permethrin, primarily used to eliminate infestations caused by external parasites. The World Health Organization (WHO) classifies the compound Permethrin as a key medicine in the Scabicides and Pediculicides pharmacological group. Pedeks, containing Permethrin, is often positioned for general household use where a topical cream or lotion is preferred for surface application.

What Type of Medicine is Pedeks?

Pedeks is a topical ectoparasiticide, a specialized type of medicine applied directly to the skin or hair to treat infestations by external organisms. It is formally classified as both a Pediculicide (targeting lice) and a Scabicide (targeting mites). This designation confirms its purpose: the targeted destruction of ectoparasites, specifically the Sarcoptes scabiei mite and various species of lice that cause pediculosis. Its identity is defined by its focused, non-systemic approach to clearing parasitic infections from the body surface.

Pedeks Composition: Synthetic Pyrethroid and Topical Form

The medicinal activity of Pedeks is derived from Permethrin, which is a powerful chemical compound belonging to the synthetic pyrethroid class. This substance is synthetic in origin, chemically manufactured to mimic the insecticidal structure of pyrethrins, which are naturally found in chrysanthemum flowers. Pedeks is manufactured as a topical preparation, typically supplied as an emulsion in a cream or lotion base. This format facilitates its direct application via the topical route of administration, ensuring the active ingredient, Permethrin, is distributed evenly across the affected area to maximize contact with the target parasites.

What is the General Purpose of Pedeks?

The general purpose of Pedeks is the elimination of active ectoparasitic infestations by rapidly neutralizing the responsible organisms. Permethrin achieves this by operating as a highly selective neurotoxin that specifically targets the nervous system of the pests. This mechanism involves disrupting sodium ion transport across the parasites' neuronal membranes, causing uncontrolled nerve firing that leads rapidly to the paralysis and subsequent death of the target organisms. This neurotoxic effect provides a clear and definitive solution for addressing the presence of mites and lice on the human body, serving as a typical initial treatment for a household member presenting with symptoms of a parasitic skin condition.

What side effects are possible with Pedeks?

Possible Side Effects and Safety Information

The safety profile of Pedeks, which contains Permethrin, is defined by adverse reactions documented in official government regulatory texts. The profile is characterized predominantly by localized reactions at the application site.

Adverse Reaction Classifications

Side effects are classified by their frequency, based on regulatory standards. The most frequently observed effects are related to the Skin and Subcutaneous Tissue Disorders System-Organ Class (SOC).

Classification Examples of Documented Reactions
Common Local burning and stinging sensation, pruritus (itching), erythema (redness), rash.
Uncommon Paresthesia (tingling or prickling sensation), headache.
Rare Hypersensitivity Reactions (severe allergic reactions).

Key Safety Patterns and Restrictions

Regulatory documentation notes specific patterns regarding the onset and persistence of effects. Local side effects are more frequently observed at the start of treatment or immediately after topical application. Furthermore, a temporary intensification of the original pruritus can be a documented post-treatment reaction.

The medicine is officially contraindicated in individuals with a known hypersensitivity to the active substance, Permethrin, to other pyrethrins, or to any excipient. A specific population-based safety consideration documented in the labeling notes that the product is generally not recommended for use in infants less than two months old.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for topical Permethrin (Pedeks) primarily addresses two distinct exposure scenarios: accidental oral ingestion and excessive topical use.

Overdose Manifestations and Severe Outcomes

Accidental ingestion of the topical preparation carries the risk of serious systemic toxicity. Documented manifestations include signs such as nausea, vomiting, headache, and dizziness. Severe outcomes listed in regulatory documents following significant ingestion may include convulsions (seizures), loss of consciousness, and pulmonary oedema.

For topical exposure, excessive or repeated use may result in localized effects, most commonly temporary skin reactions like increased irritation and erythema.

Required Emergency Actions

Immediate medical attention is required in the event of any accidental oral ingestion of the topical product, even if the individual appears asymptomatic. Regulators mandate that patients or caregivers immediately contact a Poison Control Centre or seek emergency services in this scenario. Management for suspected systemic toxicity is officially defined as symptomatic and supportive treatment, with potential requirements for hospital observation and monitoring of vital signs to manage potential severe effects. There is no specific antidote known for Permethrin toxicity.

Therapeutic Uses of Pedeks

What Pedeks Treats: Main Uses and Benefits

Pedeks is generally used across conditions presenting with acute episodes of parasitic infestation, including both scabies (mite infestation) and pediculosis (lice infestation). It is commonly used across conditions presenting with acute episodes, relevant in contexts marked by increased discomfort. It is considered relevant in conditions involving inflammatory or irritative processes and is applied across domains where additional symptomatic support is needed.


This medicine is commonly used for managing conditions presenting with acute episodes. Its application is relevant for easing symptoms that create noticeable physiological strain, particularly scabies, head lice, pubic lice, and body lice. Its use supports the patient during difficult episodes by applying across domains where additional symptomatic support is needed, which contributes to easing the overall symptom load.

Pedeks also helps address symptom clusters related to physical discomfort, such as the intense, disruptive itching (pruritus) and associated inflammatory skin reactions. The medication is commonly used when short-term symptomatic assistance is needed, such as managing infections in close contacts (family members, sexual partners) and during community outbreaks, playing a role in managing the contagious nature of the condition.


Quick Fact: Symptomatic support for Intense Pruritus (Itching)

Regulatory References

  1. NIH MedlinePlus overview on Permethrin Topical

Eligibility and Restrictions for Use

This section outlines the official population eligibility criteria for Pedeks (Permethrin topical 5%) as defined by regulatory authorities.

Eligibility Scope and Restrictions

Category Official Regulatory Status (Permethrin 5% Topical)
Populations for whom use is allowed Adults and children 2 months of age and older.
Populations for whom use is contraindicated Patients with known hypersensitivity (allergy) to permethrin, any synthetic pyrethroid, pyrethrin, or any component of the formulation.
Age-related eligibility rules Infants less than 2 months of age: Safety and effectiveness have not been established. Children under 2 years: Should be treated under medical supervision (regulatory standard in some regions).
Pregnancy eligibility Pregnancy (Category B): Use is conditional and permitted only if clearly needed.
Lactation eligibility Consideration should be given to temporarily discontinuing nursing or withholding the drug due to unknown excretion in human milk.

Eligibility Classifications

The most stringent eligibility classification is Contraindicated, which applies universally to patients with a hypersensitivity to the components. The use of Pedeks is not established in infants younger than two months. For pregnant women, use is labeled as conditional, requiring the use to be clearly needed. These classifications strictly define the population groups permitted or prohibited from using the medicine under its authorized labeling.

What should I know about interactions with other medicines?

The topical administration of Pedeks (Permethrin) results in minimal systemic absorption (less than 2% of the applied dose), which significantly limits the potential for conventional drug-drug interactions involving metabolic enzymes or drug transporters. For this reason, official regulatory labeling indicates that no systemic pharmacokinetic interactions with oral or injectable medicines are known or established.

Documented Interaction Cautions

Interaction Type Interacting Substance/Product Official Regulatory Statement
Pharmacodynamic Caution Topical Corticosteroids (e.g., creams for eczema) Use of these agents to treat skin reactions prior to Permethrin application should be withheld. This is a regulatory caution against the risk of the agents exacerbating the parasitic infestation by interfering with the body’s local immune response.
Product-Product Restriction Latex Products (e.g., barrier contraceptives) Excipients within the cream base, such as paraffin, may reduce the reliability and function of latex products, including condoms and diaphragms, if the cream is applied to the genital area.
Dietary/Herbal Interactions Food, Alcohol, Herbal Products, Supplements Official labeling states that no interactions are known or established with these substances for the topical formulation.

Summary of Regulatory Profile

Due to the low systemic exposure, the regulatory interaction profile for Pedeks focuses primarily on two key, official constraints: a pharmacodynamic caution that requires the temporary cessation of certain other topical treatments before application to ensure treatment efficacy, and a product-product restriction related to the formulation's excipients that affects the integrity of latex devices. This structure confirms that regulatory scrutiny is concentrated on local effects and formulation compatibility.

Mechanism of Action

How Pedeks Works

The activity of Pedeks, driven by the active ingredient Permethrin, is based on a highly specific neurotoxic mechanism targeting ectoparasites. It operates by disrupting the fundamental electrical processes of the parasite's nerve cells.


Targeted Blockade of Voltage-Gated Sodium Channels

Permethrin exerts its action by specifically binding to the voltage-gated sodium channels ( VGSC) found on the membranes of the parasite's neurons. It acts as an inactivation blocker, forcing these ion channels to remain open after they should have closed, leading to an uncontrolled influx of sodium ions ( Na^+). This molecular action is the initiating step that defines the subsequent mechanistic cascade.


Ectoparasite Neurotoxicity and Irreversible Paralysis

The sustained influx of Na^+ causes continuous neuronal depolarization and triggers rapid, high-frequency firing of nerve impulses throughout the ectoparasite's nervous system. This catastrophic hyperexcitation exhausts the organism's motor functions, causing sustained muscle spasms that rapidly lead to irreversible paralysis and subsequent death of the target organism.


Mechanism Constraints: Resistance Factors

The efficacy of the mechanism is constrained by specific biological factors within the parasite population. This includes target-site resistance (e.g., kdr gene mutations in the VGSC) that prevents effective Permethrin binding, and enhanced metabolic resistance via parasitic Cytochrome P450 enzymes that break down the active ingredient before it can exert its full effect.

Dosage and Administration Information

How Pedeks is Used: Official Administration Guidelines

Pedeks, a topical preparation containing Permethrin, is designed for non-systemic use, meaning it is applied exclusively to the skin (topical route) to address ectoparasitic infestations. The use pattern is structured around a single, defined application rather than a multi-day regimen, with specific preparation and contact requirements.


Application and Dosage Schedules

Condition & Strength Application Dose & Frequency Required Contact Time
Scabies (5% Cream) Single application, typically up to 30 grams for adults, covering the body from the neck down. 8 to 14 hours before washing off by showering or bathing.
Lice (1% Lotion/Rinse) Single application to saturate the affected area (hair and scalp), up to 120 mL. 10 minutes before rinsing with water.

Procedural and Timing Rules

Pedeks is intended for external use only and must be applied to clean, dry, cool skin for the 5% cream. Subsequent treatments are not applied immediately; re-treatment is only sanctioned if live parasites are observed 7 days (for lice) or 14 days (for scabies) after the initial course.

Age-Specific Instructions: The 5% cream is officially labeled for use in children as young as two months old. For both infants and geriatric patients being treated for scabies, the application site must be extended to include the scalp, hairline, temples, and forehead, a procedural modification specified in the product labeling.

The overall protocol is structured as a single, time-bound application followed by a wash-off, defining a clear usage event rather than a continuous schedule.

Recent Clinical Evidence

Research evidence / Overview of studies for Pedeks

Evidence for use in Scabies (Mite Infestation)

Research for topical Permethrin (Pedeks) primarily uses Randomized Controlled Trials (RCTs) and Systematic Reviews to study populations of adults and children with classic scabies. The primary endpoints studied include the measurement of the absence of infestation and the duration of intense itching, or pruritus, which is an outcome related to physical discomfort. Studies monitored clinical clearance rates during trials where Permethrin was evaluated alongside placebo or certain older topical treatments. Research highlights that pruritus was observed to persist for several weeks after the research indicated the infestation had been resolved.

Evidence for use in Pediculosis (Lice Infestation)

The use of topical Permethrin for pediculosis was evaluated in a large number of RCTs focused on school-aged children and adults. Researchers studied outcomes describing episodic or acute changes in infestation status, such as the full absence of live lice and viable eggs. Studies explored outcomes related to lice eggs (nits), and findings indicate that ovicidal activity was sometimes incomplete. The observation of incomplete ovicidal activity in some findings was linked to the study design feature of a mandatory second application in many research protocols.


What Remains Uncertain: Research Gaps and Limitations

One major area of uncertainty is the documented issue of resistance in both mites and lice. This means that the outcomes measured against the organisms may vary regionally, and research is ongoing to track these patterns of treatment failure. Another key limitation is that long-term effects are not fully established, as follow-up durations were typically limited to seven days to four weeks in most primary comparative studies. Furthermore, evidence quality varies across studies, especially when comparing Permethrin against the full range of alternative treatments.

Key Studies & References

  1. Permethrin Topical: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Pedeks (FAQ)

Q: What are the most common things Pedeks is prescribed for?

A: Pedeks is classified as an ectoparasiticide, meaning it is used to treat infestations caused by external organisms. According to official regulatory documents, it is primarily indicated for treating infestations with the Sarcoptes scabiei mite, which causes scabies, and for various species of lice, which cause pediculosis.

Q: How quickly does Pedeks usually start to work?

A: The active ingredient in Pedeks works by rapidly paralyzing and killing the target parasites upon contact. However, official information notes that some symptoms, such as the intense itching (pruritus) related to the infestation, may persist for several weeks after successful treatment. The persistence of itching for up to two to four weeks is described in official documents as a common post-treatment observation.

Q: What is the purpose of the black box warning (if any) on Pedeks?

A: Official regulatory labeling for Permethrin topical cream does not contain a Boxed Warning, often referred to as a black box warning. These warnings are generally reserved for drugs with specific, serious safety concerns. The key safety caution in the product information is to discontinue use if a severe allergic reaction (hypersensitivity) occurs.

Q: Does Pedeks have a warning about driving or operating machinery?

A: Pedeks is a topical medicine, and regulatory documents do not provide specific directives about driving or operating machinery. The official side effect profile lists headache and dizziness as uncommon effects; however, if a patient experiences these systemic effects, the official safety information should be consulted.

Q: Is Pedeks considered a blood pressure medicine?

A: No, Pedeks is not indicated for the treatment of blood pressure or heart conditions. Official drug classification identifies Pedeks as a scabicide and pediculicide, which is a specialized type of anti-infective used specifically for eliminating external parasites.

Q: Can Pedeks cause weight gain or weight loss?

A: Official regulatory documents, which list all common and uncommon side effects, do not include weight gain or weight loss among the documented adverse reactions associated with the topical use of Pedeks.

Q: What happens if I miss a scheduled amount of Pedeks?

A: Pedeks treatment is structured as a single, time-bound application and wash-off, not a daily regimen. If there is a question about a delayed wash-off or incomplete application, official guidance is to rinse off the original application as directed and not apply extra product. Re-treatment guidelines are defined in official instructions for when signs of live parasites reappear.

Q: Does taking Pedeks affect laboratory blood tests?

A: The official clinical pharmacology profile for Pedeks shows that less than 2% of the applied dose is absorbed into the bloodstream. Due to this minimal systemic exposure, the topical use of Pedeks is not expected to interfere with routine laboratory blood tests.

Q: How long might someone expect to be on Pedeks therapy?

A: Pedeks therapy is defined by a short, single-application period: either 10 minutes (for lice) or 8 to 14 hours (for scabies) before washing off. The medicine is not intended for continuous therapy. Re-treatment is conditional and should only occur if live organisms are seen 7 to 14 days after the initial course, depending on the condition being treated.

Q: Are there known interactions between Pedeks and herbal supplements?

A: Official regulatory labeling states that no interactions are known or established between the topical Permethrin formulation and herbal products or other supplements. Since the medicine has minimal systemic absorption, the risk of conventional drug-herb interactions is considered low.

Q: Is it normal to feel a bit tired when starting Pedeks?

A: Tiredness, fatigue, or somnolence is not listed in the official regulatory documentation as a common or uncommon side effect of Pedeks. Side effects are mainly documented as localized skin reactions.

Q: Can older adults (seniors) use Pedeks safely?

A: Permethrin topical is authorized for use in adults, including older adults. For geriatric patients, official instructions specify a procedural modification: the application site is extended to include the scalp, hairline, temples, and forehead.

Q: Is Pedeks known to interact with caffeine?

A: Official regulatory labeling states that no interactions are known or established with food or other dietary components, including caffeine. This is due to the drug's topical administration and minimal absorption into the systemic circulation.

Q: Is Pedeks addictive or habit-forming?

A: The active ingredient in Pedeks is not classified as a controlled substance by regulatory bodies. Its mechanism of action is targeted specifically at external parasites, and it is not associated with having the potential for abuse or being habit-forming in humans.

Q: Can Pedeks be crushed or split if it is a tablet?

A: Pedeks is supplied as a topical cream or lotion for external application to the skin and hair, and not as a solid oral tablet. Therefore, the instructions do not include any steps for crushing or splitting the medicine.

Q: Does Pedeks have a known interaction with multivitamins?

A: Official labeling states that no interactions are known or established between the topical formulation and vitamins, minerals, or other supplements. This applies to both individual vitamins and combined multivitamins.

Q: If I feel better, can I stop taking Pedeks?

A: Pedeks is a single-application treatment with a fixed protocol. Regardless of how quickly you feel better, the full course of treatment requires leaving the medicine on for the designated contact time (e.g., 8 to 14 hours) before washing it off, to complete the protocol defined in the official instructions.

Q: What are the official guidelines regarding Pedeks use in patients with diabetes?

A: Official regulatory guidelines only list known hypersensitivity (allergy) to the drug's components and age under two months as specific restrictions or contraindications. Diabetes is not listed as a condition that requires a special precaution for the topical use of Permethrin.

Q: Are there any known long-term side effects associated with Pedeks use?

A: The drug is intended for a single, short application, and most clinical trials had limited follow-up periods, typically ranging from seven days to four weeks. Due to this single-use protocol and the short follow-up duration of studies, long-term effects are not fully established in regulatory documents.

Q: Does Pedeks affect sleep patterns?

A: Official regulatory documentation does not list any side effects, such as insomnia or excessive drowsiness, that are directly linked to changes in sleep patterns.

Q: Is it possible for Pedeks to cause an allergic reaction?

A: Yes, it is possible. Official labeling lists Hypersensitivity Reactions (severe allergic reactions) as a Rare side effect. The medicine is officially contraindicated for use in patients with a known allergy to the active ingredient or other components of the formulation.

Q: What is the difference between the immediate-release and extended-release forms of Pedeks?

A: Pedeks is a topical cream or lotion designed for a single application with a specific contact time before being washed off. Because of this use protocol, the medicine is not formulated into traditional oral dosage forms like immediate-release or extended-release capsules or tablets.

Q: Is Pedeks considered a Schedule or controlled substance?

A: The 5% cream formulation is typically labeled as 'Rx only,' indicating that a healthcare provider's prescription is required for its use. It is not classified as a Schedule or controlled substance by regulatory bodies.

Q: What are some common reasons a doctor might choose Pedeks over other medications?

A: Pedeks is recognized on the World Health Organization's Model List of Essential Medicines. Regulatory documents highlight its targeted, non-systemic approach and its specific neurotoxic mechanism that rapidly paralyzes and kills the ectoparasites, which defines its role as a standard initial treatment for these infestations.

Q: How can I find the official FDA/EMA information leaflet for Pedeks?

A: Official, authoritative information for the active ingredient, Permethrin, is maintained by government authorities. These documents can be found in drug databases such as the FDA DailyMed, the NIH MedlinePlus, and the EMA Summary of Product Characteristics (SmPC).

Q: Does Pedeks interact with birth control pills?

A: Regulatory labeling indicates that no systemic pharmacokinetic interactions are known with oral medicines, which includes birth control pills. The only caution involving contraceptives is a product-product restriction concerning the excipients in the cream base, which may reduce the reliability of latex barrier devices if applied to the genital area.

Q: Is there a link between Pedeks and changes in mood?

A: Official regulatory documentation does not list any adverse effects related to mood changes or psychiatric disorders among the common or uncommon side effects of Pedeks.

Q: What is the role of Pedeks in treating [disease or system]?

A: The designated role of Pedeks is the targeted elimination of active ectoparasitic infestations. It serves as a primary solution for clearing parasitic skin conditions such as scabies and pediculosis from the body surface.

Q: Does the efficacy of Pedeks change over time?

A: Research documents indicate that the efficacy of Pedeks is constrained by the documented issue of target-site resistance in certain ectoparasite populations. This means that treatment outcomes may vary regionally, and tracking these resistance patterns is an ongoing area of research.

Q: Are there any restrictions on strenuous activity while taking Pedeks?

A: Since Pedeks is a topical medicine with minimal systemic effects, official guidelines do not list any specific restrictions on engaging in strenuous activity after the product has been properly washed off according to the required contact time.

Q: Is Pedeks a medication that requires a special prescription?

A: In many regions, the 5% cream formulation is labeled as 'Rx only,' indicating that a healthcare provider's prescription is required for its use. Its regulatory classification means that a healthcare provider's prescription is required for its use.

How should Pedeks be stored and disposed of?

Storage and Disposal Requirements for Pedeks

The official regulatory labeling strictly defines the necessary conditions for storing and discarding Pedeks cream.

Official Storage Conditions

Requirement Regulatory Statement
Temperature Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). Do not store above 25 C.
Protection Do not freeze. Keep in the original container and keep the lid tightly closed to protect from moisture and light.
Child Safety Keep this and all medications out of the sight and reach of children.
Handling Note Be aware that materials contaminated with the cream are easily ignitable and must be kept away from naked flames or other fire sources.

Disposal Instructions

Unused or expired Pedeks must not be disposed of via wastewater or household waste. Consult a pharmacist or follow the instructions of your local solid waste management authority for the proper handling and discarding of the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pedeks found in:

A-Z Index: